Abstract library

1901 results for "pulmonary neuroendocrine tumors".
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#598 Pulmonary Neuroendocrine Tumors: Long-Term Survival After Resection and Prognostic Factors
Introduction: Patients with primary pulmonary neuroendocrine tumors (PNT) are often clinically manifested with cough and hemoptysis. Surgery is the preferred treatment.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Jie He
Authors: Chi Y H B L, Gao S G, Du F, Wang J W, ...
#191 Immunohistochemical Analysis of Epithelial-Mesenchymal Transition Markers in Neuroendocrine Tumors of the Lung
Introduction: The increased motility and invasiveness of cancer cells in the first phase of metastasis are reminiscent of epithelial–mesenchymal transition (EMT) during embryonic development.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Jose Galván
#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PD Dr. Patricia Grabowski
#1124 Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)
Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Margot Bucau
#47 Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in Patients with Neuroendocrine Tumors
Introduction: Carcinoid heart disease (CHD) is a known complication of neuroendocrine tumors (NETs), particularly of those arising from the small intestine, appendix and proximal colon (previously known as mid-gut carcinoids). CHD is characterized by right heart fibrotic lesions and has traditionally been defined by the degree of valvular involvement, most commonly in the form of tricuspid regurgitation. Right ventricular (RV) dysfunction due to mural involvement may also be a manifestation. Connective tissue growth factor (CCN2) is upregulated in many fibrotic disorders. Increased tumor expression of CCN2 has been shown in patients with small intestinal NETs associated with peritoneal fibrosis. At present, its role in carcinoid heart disease is unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Deidi S Bergestuen
#994 Predictive Biomarkers of Response in Patients with Extrapulmonary Neuroendocrine Tumors (EPNET) Treated with Platin-based Chemotherapy
Introduction: EPNET, particularly advanced and Grade 3 (G3) tumors are often treated with chemotherapy. While many patients experience tumor response, those rarely live for more than two years. Predictive markers could potentially help us to tailor the best treatment for these patients (pts).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: MD Juliana F Rego
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#168 Neuroendocrine Tumors - Imaging Abdominal Complications
Introduction: Neuroendocrine tumors mostly arise from the gastrointestinal tract and pancreas but also from bronchopulmonary or any other organ. Abdominal complications are usually associated with the primary GI tract tumor.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Joana Ip
Authors: Ip J, Claro I, Duarte I, ...
#1058 Epidemiologic Analysis of Neuroendocrine Tumors in Cancer Center: Tianjin, China
Introduction: An increased incidence of neuroendocrine tumors (NETs) has been reported worldwide.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Jian Wang
Authors: Wang J, Sun Y S, Wang X, Hao J, ...